Women's Health Diagnostics Market To Reach $31.4 Billion By 2030

Women's Health Diagnostics Market Growth & Trends

The global women’s health diagnostics market size is expected to reach USD 31.4 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.3% from 2023 to 2030. Rising adoption of point-of-care diagnostics and growing incidence of various chronic and lifestyle diseases are among the key factors stimulating the growth of the market. Besides this, introducing various awareness programs is also anticipated to work in favor the market during the forecast period. For instance, in 2014, the European Commission launched joint action for European Guide on Quality Improvement in Comprehensive Cancer Control.

Women’s health diagnostics is witnessing high growth due to increased funding from various organizations. For instance, in May 2015, Abcodia received funding of USD 8.0 million from Cambridge Innovative Capital, Scottish Equity Partners, Albion Ventures, and UCLB to launch Risk of Ovarian Cancer Algorithm (ROCA) test in the U.K. for early detection of ovarian cancer.

On the basis of end use, the market has been bifurcated into hospital & diagnostics centers and home. Hospitals and diagnostic centers accounted for a larger share in the market due to high number of visits to hospitals and more reliable detection.

The market in Asia Pacific is likely to witness significant growth over the coming years. The growth of the market can be attributed to increasing investments in healthcare, growing focus of international device manufacturers on strengthening their distribution networks within the region, and epidemiological shift from infectious diseases to chronic diseases within regional boundaries.

 Request a free sample copy or view report summary: Women’s Health Diagnostics Market Report

Women's Health Diagnostics Market Report Highlights

• Increasing investments by governments and private bodies and rising disposable income are providing a push to the market

• Cancer accounted for the highest share in the market in 2017. The segment will register noteworthy growth during the forecast period owing to availability of early detection tests and government initiatives to tackle cancer

• Prenatal testing is estimated to be the fastest growing segment during the same period owing to rising prevalence of prenatal diseases, increasing maternal age, surging healthcare expenditure, and development of advanced diagnostic tests

• Geographically, North America dominated the market and accounted for the largest revenue share of 44.87% in 2022. It is anticipated to maintain its dominance through 2025, thanks to widening base of diagnostic and imaging centers, mounting cases of cancer, growing awareness about fertility testing, and spiraling adoption of point-of-care testing devices

Women's Health Diagnostics Market Segmentation

Grand View Research has segmented the global women’s health diagnostics market based on application, end-use, and region:

Women's Health Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer

• Infectious disease

• Osteoporosis

• Pregnancy & fertility

• Prenatal

Women's Health Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Laboratory

• Home Care

• Others

Women's Health Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players of Women's Health Diagnostics Market

• F. Hoffmann-la Roche Ltd.

• Siemens Aktiengesellschaft

• Quest Diagnostics Incorporated

• Ge Healthcare

• Koninklijke Philips N.V.

• Abbott Laboratories

• Becton, Dickinson, and Company,

• Hologic, Inc.